News | May 14, 2025
Biocon Q4 FY25 consolidated PAT jumps 153% to Rs. 344 Cr
For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.
For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.
he inspection covering the sterile drug product filling and packaging line, quality systems and quality control laboratories concluded compliance with the principles and guidelines of Good Manufacturing Practice
Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
This approval marks a significant milestone in OneSource’s ongoing commitment to quality and regulatory compliance
Asahi Kasei Life Science covers a broad range of bioprocess products and services
Awards highlight Avantor's commitment to the Biopharma industry
Being a premium partner for pharmaceutical companies by contributing to safety and productivity of pharmaceutical manufacture
Lonza’s new simplified and streamlined operating model is designed to support its One Lonza vision and strategy
Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety endpoints compared to IV KEYTRUDA in combination with chemotherapy
Subscribe To Our Newsletter & Stay Updated
